NSE: ANUHPHR · BSE: 506260
ANUH PHARMA LIMITED
Manufactures active pharmaceutical ingredients (APIs), also known as bulk drugs, which are the chemical compounds used by other drug makers to produce finished medicines. The product slate is expanding into regulated-market molecules, with new additions cited as Vonoprazon Fumarate, Pretomanid, and Edoxaban Tosylate. Revenue comes from two streams: domestic sales (around 54% of revenue) and exports (around 46%), with Africa (33% of exports), Asia (35%), and Europe (24%) as the named export geographies. The manufacturing base produced 1,733 metric tonnes in FY26 (up about 25% year-on-year), running against installed capacity of 2,400 MTPA, and the facilities cleared USFDA and EU GMP inspections with zero 483 observations. Costs are dominated by raw materials at 66.1% of revenue, with employee cost at 3.4% and other operating expenses at 10.9%. Depreciation is 1.5% and capex 1.0% of revenue, indicating a relatively capital-light profile. EBITDA margin compressed to 8.56% in FY26, with net profit of Rs. 41.05 crore on revenue of Rs. 771.66 crore. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Domestic API sales (54%), Export API sales (46%). API manufacturer with export exposure to regulated and semi-regulated markets; capital-light with low capex at 1.0% of revenue.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 487 | 527 | 647 | 662 | 772 |
| EBITDA (ex other income) | 47 | 51 | 75 | 61 | 62 |
| margin % | 9.6 | 9.7 | 11.6 | 9.2 | 8.0 |
| Owners' profit | 31 | 36 | 60 | 47 | 41 |
| EPS, as reported (₹) | 6.10 | 7.22 | 11.98 | 9.45 | 4.10 |
| ROE % · ROCE % | 14.3 · 18.5 | 15.0 · 19.6 | 20.6 · 26.8 | 14.5 · 18.8 | 11.7 · 15.4 |
| Debt / equity (x) | 0.01 | 0.00 | 0.01 | 0.03 | 0.00 |
| Cash from operations | 29 | 54 | 13 | 37 | (3) |
| Capex | (2) | (2) | (5) | (20) | (8) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 160 | 198 | 186 | 372 | 197 | 202 | 194 |
| Profit before tax | 18 | 13 | 17 | 11 | 21 | 18 | 16 | 17 |
| Net profit | 15 | 10 | 12 | 8 | 16 | 13 | 12 | 11 |
| EPS (₹) | 3.00 | 2.06 | 2.49 | 1.66 | 1.59 | 1.34 | 1.17 | 1.14 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,821 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,56,096 | 87.7 | 15.28 | 66.1 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,55,015 | 73.2 | 8.82 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,21,232 | 110.8 | 22.32 | 67.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,18,522 | 26.5 | 4.01 | 15.3 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,890 | 34.6 | 2.93 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,690 | 32.5 | 3.18 | 16.8 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,01,982 | 49.9 | 6.16 | 28.1 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 15.3 | 30.2 | 34 of 158 | 79% |
| P/B | 2.3 | 3.1 | 64 of 163 | 61% |
| ROCE | 15.3 | 10.8 | 61 of 183 | 67% |
| ROE | 11.7 | 9.8 | 70 of 166 | 58% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| EBITDA margin | 10.0 | 17.5 | 121 of 165 | 27% |
| Revenue growth | 3.9 | 16.3 | 116 of 161 | 28% |
| Profit growth | 37.6 | 30.9 | 75 of 158 | 53% |
| Market cap | 801 | 801 | 91 of 181 | 50% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 26 Oct 2026 · Board to approve September 2026 quarterly and half-year results | results | low | — | — |
| 21 Oct 2026 · Anuh Pharma takes possession of Vanquest Pharma manufacturing facility | capex operations | high | — | — |
| 16 Oct 2026 · Anuh Pharma to acquire API manufacturing facility from Vanquest Pharma for Rs 72.9 Cr | strategic transactions | high | — | — |
| 13 Oct 2026 · Board approves manufacturing expansion, up to Rs 75 cr loan | capex operations | high | — | — |
| 13 Oct 2026 · Board approves investment and ₹75 cr loan proposal for capacity expansion | credit debt | high | — | — |
| 12 Oct 2026 · Compliance certificate under SEBI Regulation 74(5) for Q2 FY26 | compliance | minimal | — | — |
| 28 Sept 2026 · Trading Window Closed Ahead of Q2 FY27 Results | compliance | minimal | — | — |
| 18 Sept 2026 · Income Tax demand of Rs 9.93 lakh for AY 2018-19; company to appeal | regulatory legal | high | — | — |
| 19 Aug 2026 · Q1 FY27: profit up 38%, EBITDA margin expands to 9.99% | investor communications | medium | — | — |
| 14 Aug 2026 · Anuh Pharma AGM 2026: Rs 1.50 dividend, all 9 resolutions passed | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.